heterogeneity of cell populations, species, LPA receptor expression profi les, LPA concentration used, and the culture conditions of the cell lines. In rodents, LPA was reported to stimulate, inhibit, or not affect NS/PC proliferation (13) (14) (15) (16) . Further, LPA has been shown to be a survival factor, a pro-apoptotic agent or a prodifferentiation factor of NS/PCs (16) (17) (18) . Comparably, LPA has also been described as a proliferative, survival, or prodifferentiation factor in some neuroblasts but not all ( 8 ) . It was recently shown that LPA can induce fetal hydrocephalus in the mouse by an aberrant activation of Lpa 1 on NS/PCs during development ( 19 ) . LPA also acts through the Rho pathway to induce morphological rearrangements in neuroblasts and neurons (20) (21) (22) (23) (24) , including actin polymerization ( 21 ) that leads to the formation of retraction fi bers, neurite retraction ( 21, (25) (26) (27) (28) (29) (30) (31) (32) , cell rounding ( 26, 29, 33, 34 ) , cluster compaction (35) (36) (37) (38) , and growth cone collapse ( 21, 26, 27 ) .
The study of LPA in human NS/PCs and neurons is still extremely limited. Although we briefl y reported that LPA inhibits the ability of hESC-derived NS/PCs to form neurospheres, we did not attempt to characterize this biological effect and the signaling pathways associated ( 39 ) . We also previously showed that when two-week-old hESC-derived neurospheres were plated onto laminin or fi bronectin, LPA inhibited their neuronal differentiation through the Rho/ROCK and phosphatidylinositol 3-kinase (PI3K)/ Akt pathways ( 39 ) . This effect was linked to an antidifferentiation effect of LPA, as no modifi cation in apoptosis or proliferation could be detected on these plated neurospheres ( 39 ) . Hurst and colleagues, however, reported that LPA stimulates proliferation and cell-rounding of hESC-derived neuroepithelium cell line (NEP), a stable line enriched in hESC-derived NS/PCs and grown under adherent conditions ( 40, 41 ) . These variations may be due to culture conditions or cell origin.
Here and given the potential differences of hESCs and human iPSCs, we dissected LPA's effects on the progressive neural differentiation on both types of hPSCs, thus allowing to directly compare LPA signaling in hESCs and human iPSCs. Our differentiation protocol allows to assess effects of LPA on NS/PCs during their neural differentiation and on NS/PC-derived neurons. While our previous study concentrated on the impact of LPA on the neuronal and glial differentiation of hESC-derived NS/ PCs ( 39 ) , this current study assessed the effects of LPA at an earlier stage of neuralization, namely, the expansion of NS/PCs, from both hESCs and human iPSCs. Further, we assessed whether the data obtained on the neuronal and glial differentiation of hESCs were relevant to human iPSCs, allowing us to draw conclusions on the similarity of LPA's effects across these two different cell types. Finally, we assessed LPA's effects on the morphology of early human neurons derived from NS/PCs. This study thus provides a comprehensive assessment of the role of LPA in these various differentiation stages on hESCs and human iPSCs. Because LPA is released upon infl ammation and is involved in neurotrauma and various CNS diseases ( 1 ) , appreciating its role on neurogenesis and is found to be expressed in various CNS regions during development or adulthood, and its activity is modifi ed following various physiopathological events ( 1 ) . In the CNS, LPA can target most cell types and plays roles in a variety of developmental and pathological processes, including neurogenesis, neuropathic pain, neural injury, schizophrenia, epilepsy, and memory impairment ( 1 ) .
Neural stem/progenitor cells (NS/PC) have been extensively studied, with the aim of using endogenous and/ or donor NS/PCs to replace neurons and restore circuitry in a neurodegenerative microenvironment. In theory, human embryonic stem cells (hESC) and human induced pluripotent stem cells (iPSC) are a great source of cells to generate NS/PCs and progeny, which could potentially be used for transplantation and also to provide insight into human neurogenesis. Although not identical, hESCs and iPSCs seem very similar, but the extent of the variations and similarities between the two types of cells remains open ( 9 ) . Hence, comparing their differentiation potentials and response to specifi c signaling molecules is still required to allow drawing conclusions on whether hESCs and iPSCs show critical differences. It was previously shown in hESCs that the bone morphogenetic protein inhibitor noggin induces neuroectodermal differentiation, as shown by the expression of SOX2, paired box protein 6, and nestin and a lack of expression of early mesoderm or endoderm markers ( 10 ) . Once dissected, these colonies are propagated in suspension in neural basal media (NBM) supplemented with basic fi broblast growth factor (bFGF) and epidermal growth factor (EGF), where they aggregate and form a spherical-like cluster named neurosphere, which consists of a heterogeneous population of NS/PCs ( 10 ) . Neurospheres can be differentiated to give rise to neurons and glia when plated onto laminin or fi bronectin substrates, respectively. Hence, this differentiation protocol allows the progressive neural patterning of human pluripotent stem cells (hPSC, noggin stage), effi cient generation and expansion of NS/PCs (neurosphere stage), and subsequent differentiation into early neurons and glial cells ( 11 ) . Other protocols of differentiation have been established for hESCs ( 12 ) , including protocols that maintain NS/PCs as a monolayer instead of a neurosphere, but they are less defi ned. This overall method allows to precisely divide the whole differentiation process into defi ned stages and to effi ciently generate human neural progenitors and early neurons, rendering this technique robust and well defi ned. These features make this protocol highly useful for the study of fundamental signaling mechanisms involved in NS/PC multipotency and expansion. Unraveling these mechanisms may allow for better and more effi cient techniques to use human NS/PCs, either endogenous or exogenous, to treat neurodegeneration and infl ammation of the CNS by characterizing, for instance, how the cellular environment modifi es NS/PC fate in term of survival and differentiation.
LPA's effects on NS/PCs and neuroblasts seem to vary depending on the origin of the cells ( 8 ) . These differences might be the consequence of discrepancies in terms of cell source (different lines and differentiation stages), appropriate conjugated secondary antibodies (Alexa Fluor 555 or 488, Cy3, Molecular Probes-Invitrogen). Nuclei were counterstained with 4 ′ ,6-diamidino-2-pheylindole (DAPI, 1:1000, Sigma-Aldrich). Specifi city of the staining was verifi ed by the appropriate negative control immunoglobulin fraction (see Fig. 4G, H , Fig. 5F , G ). For monolayer NS/PCs, cells were permeabilized with PBS-Tween/0.3% Triton X-100 following PFA fi xation.
Cell culture and neural induction of hPSCs
The iPS (Foreskin) 4 clone 1 and clone 2, abbreviated iPS1 and iPS2 ( 42 ) , and the hESC line ENVY (ES Cell International) were cultured as described ( 43, 44 ) . Neuronal induction by noggin (R and D, 500 ng/ml) was performed as described in ( 11 ) . Noggin-treated cells were dissected after 14 days and were further subcultured in suspension in NBM together with bFGF (Millipore) and EGF (R and D, 20 ng/ml each) to form neurospheres ( 45 ) .
NS/PC monolayer culture
The monolayer culture of NS/PCs was generated as previously reported ( 46 ) with some modifi cations. Briefl y, two-week-old neurospheres cultured with NBM supplemented with bFGF and EGF were collected and dissociated by disaggregation with Trysin-EDTA (Invitrogen). The enzymatic reaction was stopped using soybean trypsin inhibitor (Sigma). The dissociated cells were seeded in NBM supplemented with growth factors onto precoated tissue culture dishes with laminin 1 µg/cm 2 (SigmaAldrich) to generate a monolayer of NS/PCs. The medium was changed every second day. NS/PCs were further passaged with accutase (Sigma). Medium was changed every second day, and cells were cultured for three weeks. All experiments were consistently conducted on less than passage 5 monolayered NS/PCs.
Neurosphere formation assay
Noggin-treated cells were harvested after 14 days by dissecting and further subcultured as neurospheres, in suspension in NBM together with bFGF and EGF (20 ng/ml each), in the presence or in the absence of LPA (complete with any inhibitor used), with medium changed every second day ( 39 ) . Each condition was performed in at least eight individual wells and repeated in at least three independent experiments. Assessment of neurosphere formation was performed after 7 days.
Neuronal and glial differentiation of neurosphere
After two weeks in suspension, neurospheres cultivated in NBM with bFGF and EGF were plated as previously described ( 11 ) onto poly-l-lysine/laminin-coated (Sigma, 10 and 5 µg/ ml, respectively) or poly-l-lysine/fi bronectin-coated (Millipore, 10 µg/ml) dishes in NBM lacking growth factors to induce neuronal and glial differentiation, respectively, allowed to attach, and incubated in the presence or in the absence of LPA (complete with any inhibitor used) for fi ve days ( 39 ) . For each type of experiment, after attachment, medium was changed every second day. Pictures were taken of each individual well (inverted microscope Olympus IX71 and Cell IR software) following fi ve days in culture. The cells were then fi xed with 4% PFA/PBS.
Quantifi cation of neuron-forming spheres
Quantifi cation was performed by counting the number of spheres from which neuronal outgrowth was observable ( 39 ) . In some cases neurospheres failed to attach, independently of the treatments, and these fl oating neurospheres were excluded from quantifi cation. understanding its impact, specifi cally on NS/PCs and progeny, is relevant to transplantation work. LPA might be the environmental cue that is able to modify the behavior of NS/PCs and their derivatives during infl ammation after neurotrauma.
MATERIALS AND METHODS

Ethics
All experiments were approved by the Human Research Ethics Committees of the University of Melbourne (Approvals 0605017 and 0830010).
Reagents
Dilutions of LPA (Sigma-Aldrich, Castle Hill, Australia) were made in 0.1% fatty acid-free BSA (fi nal concentration 0.01% BSA; Sigma-Aldrich). Cells were treated with LPA (up to 10 µM), LPA 1 /LPA 3 antagonists Ki16425 (Sigma-Aldrich, 10 µM), LY294002 (Promega, 10 µM), Y27632 (Biomol, 1 µM), GW9662 (Cayman Chemicals, 1 µM), cell-permeable C3 Transferase (Cytoskeleton, 1 ng/ml, pretreament 4 h), Pertussis toxin (PTX, Biomol, 10 ng/ ml, pretreament 18 h). Unless otherwise specifi ed, inhibitors were added to cells 30 min prior to addition of LPA to the culture medium on the fi rst incubation.
RT-PCR
mRNA was isolated from undifferentiated hPSCs, noggintreated hPSCs, NS/PCs in neurospheres, and monolayers of NS/ PCs using Dynabeads Oligo (dT)25 (Dynabeads). RT-PCR were conducted using High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems), following the manufacturer's instructions. A negative control ( Ϫ RT) consisting in the absence of reverse transcriptase was performed to check the absence of genomic DNA. qPCR was carried out using TaqMan Universal master mix (Applied Biosystems) and the 7900HT Fast Real-Time PCR system (Applied Biosystems) and TaqMan gene expression assays for LPA [1] [2] [3] [4] [5] and ATX (Applied Biosystems). TaqMan gene expression assays for LPA 1 (Hs00173500_m1), LPA 2 (Hs00173704_m1), LPA 3 (Hs00173857_m1), LPA 4 (Hs00271072_s1), LPA 5 (Hs01051307_ m1), ATX (Hs00196470_m1), PLA2-group IIA (Hs00179898_ m1), ROCK1 (Hs01127699_m1), and ROCK2 (Hs00178154_m1) were used (Applied Biosystems). The relative quantitation was achieved by applying the comparative CT method ( ⌬ ⌬ CT) in which the mRNA levels were normalized against the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA (TaqMan gene expression assay Hs99999905_m1) or ␤ -actin (Hs99999903_ m1) with LPA 5 used as the reference. Q-PCR reaction of the nonreverse-transcribed sample was also conducted for each Taqman probe above to check the genomic DNA contamination in the sample and the specifi city of the probes.
Immunofl uorescence
Following fi xation with paraformaldehyde (PFA) 4% for 10 min, cells were blocked in a 10% fetal calf serum-PBS 0.1% Tween 20 (PBT, 60 min) and immunostained with the following primary antibodies: mouse anti-␤ III-tubulin (Millipore); rabbit anti-glutamate aspartate transporter (GLAST, Millipore); rabbit anti-glial fi brillary acidic protein (GFAP, DAKO); mouse anti-A2B5 (Millipore); rabbit anti-nestin (Millipore); rabbit antidoublecortin (DCX, Abcam); mouse phospho-myosin light chain (MLC) 2 (Ser19); and rabbit phospho-cofilin (Ser3) (77G2, Genesearch). Cells were then immunostained with the LPA treatment in the maintenance of monolayer NS/PC culture NS/PCs were seeded onto laminin-precoated 24-well plates in NBM supplemented with growth factor (bFGF and EGF, 20 ng/ml each). After two days, medium was changed and supplemented with LPA and fi xed in PFA 4% 18 h later.
Cell morphology assays of the differentiated neurons derived from monolayer NS/PC culture
Neurons cultured for three weeks on poly-l-lysine/laminincoated slides were placed on the heated stage of an inverted microscope (Olympus) equipped with phase-contrast optics and temperature control. During time-lapse recording, the plated neurons were maintained in 25 mM HEPES-buffered NBM (pH 7.4) at 37°C and observed continuously using a camera connected to time-lapse software (Axiovision and Olympus IX71). LPA at different concentrations (0.1, 1, and 10 µM) was applied during time-lapse recording. Images were acquired using 5 s interframe intervals.
siRNA knockdown of ROCK
Monolayer NS/PCs were passaged into complete NBM media without antibiotic one day before transfection at 2.5-5 × 10
5 / well in 6-well plates. Knockdown of ROCKI and/or ROCKII was performed using Dharmacon SMART pool ON-TARGETplus ROCK1 siRNA (L-003536-00-0005) and ON-TARGETplus ROCK2 siRNA (L-004610-00-0005), which were already demonstrated to be specifi c in hESC ( 47 ) . Control for transfection was done using ON-TARGETplus NonTargeting Pool (D-001810-10-05). Specifi c siRNA (25 nM) for each pool was mixed with Dharmafect II, following Dharmacon siRNA Transfection's protocol. Measurement of knockdown effi ciency and survival were respectively performed at 48 h and 72-96 h following transfection. Quantifi cation of ROCKI and ROCKII mRNA levels were determined by qPCR. Expression levels of corresponding genes were normalized to the housekeeping gene ␤ -actin and expressed as the percentage level over the control. At 48 h post transfection, cells were passaged onto laminin-coated chamber slides. At 72 h post transfection, LPA (10 M) was added for 18 h prior to TUNEL assay.
Statistical analysis
All sets of experiments were performed at least three times in triplicate, unless specifi ed ( n refers to the number of independent experiments performed on different cell cultures). Datasets were expressed as means ± SEM. Signifi cance of the differences was evaluated using the t -test or the one-and two-way ANOVA followed by the Newman-Keuls test for multiple comparisons. Statistical signifi cance was established at * P < 0.05, ** P < 0.01, and *** P < 0.001.
RESULTS
Neural differentiated hPSCs express LPA 1-5 and LPA producing enzymes mRNA
We performed qPCR analysis of hPSCs at the different stages of progressive neural differentiation (undifferentiated cells, noggin-treated cells, and neurospheres) to characterize their expression profi le ( Fig. 1 ) . All of the undifferentiated and the differentiated hPSCs expressed LPA [1] [2] [3] [4] [5] , ATX , and sPLA 2 mRNA ( Fig. 1 ) , with LPA 2 and
Cell morphology assays
Six-to seven-day-old neurospheres cultured on poly-l-lysine/ laminin-coated slides were placed on the heated stage of an inverted microscope (Olympus) equipped with phase-contrast optics and temperature control. During time-lapse recording, the plated neurospheres were maintained in 25 mM HEPES-buffered NBM (pH 7.4) at 37°C and observed continuously using a camera connected to Axiovision time-lapse software (Carl Zeiss). Various concentrations of LPA and/or selected inhibitors were applied during time-lapse recording. To observe reversibility of LPA's effect, LPA was withdrawn from the culture medium and replaced by normal 25 mM HEPES-buffered complete medium, followed by time-lapse recording at indicated times. Images were acquired using 5 s interframe intervals. The pictures were then assessed for morphological modifi cations of plated neurosphere and neurite retraction. At least three independent experiments were performed for each treatment.
Apoptosis and proliferation assays
Cell apoptosis was quantifi ed by measuring numbers of condensed nuclei with terminal transferase dUTP nick end labeling (TUNEL) immunocytochemistry. TUNEL analysis was performed using the In Situ Cell Death Detection Kit (Roche) following the manufacturer's instruction. Proliferation was assessed by staining with Ki67 (Thermo Fisher Scientifi c, Clone SP6). Briefl y, day 7 neurospheres were collected, manually dissociated, centrifuged onto glass slides (4 min at 1,000 rpm, Shandon Cytospin 4, Thermo Fisher Scientifi c), air dried, fi xed with 4% PFA, and permeabilized with 0.1% Triton X-100 before immunostaining with a TMR Red-conjugated TdT enzyme or Ki67, respectively. Apoptosis and proliferation were also assessed on laminin-plated, twoweek-old neurospheres treated with or without LPA (10 M, 18 h) as described in Ref. 39 . Cell nuclei were counterstained with DAPI. Specifi city of the staining was verifi ed by the absence of staining in negative controls without the TdT enzyme or negative isotype. Apoptosis and proliferation were respectively quantifi ed by manually counting TUNEL-positive cells and Ki67-positive cells as a percentage of total cell number, counting at least 1,000 cells per treatment by using Image J software (National Institutes of Health).
RhoA activation assay
Active RhoA was measured using the G-LISA RhoA activation assay biochem kit (Cytoskeleton, colorimetric assay) according to the manufacturer's instructions. Briefl y, monolayered NS/PCs were cultured for two days in NBM supplemented with bFGF and EGF (20 ng/ml) until they reached 30-50% confl uency. Concentration of bFGF and EGF was reduced to 10 ng/ml for one day and then removed overnight prior to treatment. Cells were treated or not with LPA 10 µM for 1, 3, 5, 15, and 30 min. Following treatments, cells were rinsed twice with cold PBS, rapidly scraped, lysed in a cold premixed lysis buffer with protease inhibitor on ice, and centrifuged (1,000 g , 4°C, 1 min). Supernatants were collected and snap-frozen in liquid nitrogen. Some aliquots were taken for protein concentration measurement. Following adjustment of protein concentration, G-LISA was then processed according to manufacturer's kit instruction. The optical density (OD) was read at 490 nm using a 96-well microplate reader (Bio-Rad).
NS/PC monolayer differentiation
To induce neuronal and astrocytic differentiation, the monolayer NS/PCs were replated onto poly-l-ornithine/laminintreated wells at 1-5 × 10 4 cells/cm 2 . Medium was changed every second day, and cells were cultured for three weeks. (neurosphere stage). Similarly, an increase of ATX mRNA expression was observed in both noggin-treated cells and neurospheres. LPA 3 and LPA 5 mRNA were downregulated upon neural differentiation, and no signifi cant modulation was observed for LPA 2 and LPA 4 . Very low levels of sPLA 2 were observed at all stages of differentiation. Similar trends were observed in the other lines tested ( Fig. 1E, F ) . Given the similar trend of expression of LPA [1] [2] [3] [4] [5] , ATX , and sPLA 2 mRNA in neurospheres from the two clones of iPSCs, we assessed most biological effects of LPA in iPS1 and compared them with hESCs. LPA 4 mRNA being the most abundant. LPA 5 mRNA was expressed at very low levels in neurospheres obtained from all lines relative to LPA [1] [2] [3] [4] ( Fig. 1A-C ) . To examine the expression profi le of LPA receptors, ATX, and sPLA 2 at each differentiation stage, the mRNA expression levels of each gene were presented in comparison to their corresponding levels in undifferentiated hPSCs ( Fig. 1D-F ) . Fig. 1D provides an illustration of the data obtained with iPS1. Temporal upregulation of LPA 1 mRNA expression was found during early differentiation (noggin-treated stage), followed by a downregulation during later differentiation ) profi le of LPA [1] [2] [3] [4] [5] , ATX in neurosphere relative to LPA 5, in iPS1 (A), iPS2 (B), and hESCs (C). (D-F) mRNA profi le of undifferentiated and progressively differentiated into NS/PCs (noggin-treated and neurosphere) relative to undifferentiated iPS1 (D), iPS2 (E), and hESCs (F). The mRNA expression levels were normalized against the level of GAPDH mRNA ( ⌬ Ct) with the level of LPA 5 (A-C) or LPA [1] [2] [3] [4] [5] , ATX , and sPLA 2 of the undifferentiated hPSCs (D-F) used as the reference genes ( ⌬ ⌬ Ct). Data were obtained from at least three independent experiments and expressed as means ± SEM of triplicates of each sample. The statistical analysis was established by one-way ANOVA; * P < 0.05; ** P < 0.01; *** P < 0.001. ( Figs. 2C and 3A, F ) . As exemplifi ed in Fig. 2A -C in iPS1, LPA strongly inhibited sphere formation in a dose-dependent manner (LPA, 10 µM: 10.4 ± 3.8% of sphere formation compared with control: 59.4 ± 7.5%, n > 3, P < 0.001; Fig. 2A-C ) . This effect was associated with a decrease in proliferation (36.11 ± 10.1% of
LPA inhibits neurosphere formation through activation of the Rho/ROCK pathway
We previously reported that one dose of LPA (10 µM) signifi cantly inhibits neurosphere formation of hESC-derived NS/PCs, without further description of this effect ( 39 ) . Here, we observed a similar effect in two clones of iPSCs and characterized this in both iPSCs and hESCs ( Figs. 2 and 3 ) . Interestingly, LPA-mediated inhibition of and/or Ki16425 (10 µM, E), GW9662 (1 µM, F), C3 (1 ng/ml, G), Y27632 (1 µM, H), and PTX (10 ng/ml, I). The specifi c inhibitors were preincubated as specifi ed in Materials and Methods prior to LPA addition and maintained in the culture medium for the entire differentiation period. Data are expressed as mean ± SEM from at least three independent experiments. The statistical analysis was established by one-way ANOVA analysis (C-I); * P < 0.05; ** P < 0.01; *** P < 0.001. Data presented were obtained with iPS1. Scale bar: 200 µm. ( Fig. 4A , B ) , could be subcultured for several passages, reformed neurospheres in suspension culture ( Fig. 4C ) , could be differentiated into neurons and glial cells ( Fig. 4D-F ) and also express mRNA for LPA receptors and producing enzymes ( Fig. 4I ) . Similar trends in LPA-mediated effects were observed between suspension culture and adherent culture of NS/ PCs, thus allowing parallel conclusions to be made between the two culture systems ( Fig. 4J-M ) . Adherent NS/PCs were cultured in the presence or absence of LPA, followed by Rho activation measurements by ELISA. A basal level of Rho activation was detected on control NS/PCs. As shown in Fig. 4N , LPA induced a rapid increase of active RhoA (GTP-Rho) in NS/PCs, which was biphasic with an elevation that peaked at 1 min post exposure followed by a sustained but lower activity for at least 30 min. This result directly demonstrates that LPA stimulates Rho in NS/PCs and that this activation critically modulates NS/PC expansion.
To exclude potential off-targets of the ROCK kinase inhibitor Y27632 despite its high specifi city, we further confi rmed our results by a molecular approach consisting of knocking down ROCKI and ROCKII by siRNA in monolayered NS/PCs, individually or together ( Fig. 4O, P ) . Following 48 h post transfection, single siRNA treatment for either ROCKI or ROCKII specifi cally knocked down its corresponding gene while their dual knocking down resulted in 75.6 ± 7.0% and 76.2 ± 4.3% downregulation of ROCKI and ROCKII mRNAs ( Fig. 4O ) . When monolayered NS/PCs were knocked down for both ROCKI/ROCKII, the apoptosis induced by LPA was abolished, demonstrating the involvement of ROCK in LPA's effect ( Fig. 4P ) .
LPA inhibits the neuronal differentiation of iPSCs through the Rho/ROCK and PI3K/Akt pathways
LPA did not modify glial differentiation of iPSC-derived neurospheres but inhibited their neuronal differentiation ( Fig. 5A -G ) . This effect was dose dependent and ROCK and PI3K/Akt dependent ( Fig. 5H, I ). As shown in Fig. 5I , LPA's effect on human iPSC-derived NS/PCs was partially abolished by the sole application of Y27632 or LY294002 but was abolished in the presence of both inhibitors. These effects were observed in both iPSC lines tested. As previously observed with hESC-derived neurospheres ( 39 ), we confi rm here that LPA acts through an inhibition of differentiation rather than by modifying proliferation or apoptosis of these two-week-old neurospheres. Indeed, neurospheres plated onto laminin in the presence of LPA (10 µM, 18 h) did not show modifi cation of Ki67 or TUNEL when compared with control conditions (no LPA; Fig. 5J ).
LPA induces morphological rearrangements of hPSCderived early neurons through the Rho/ROCK pathway
After six days of plating, neurospheres had already given rise to ␤ III-tubulin-positive early neurons, which radially migrate out from the edges of the neurospheres ( Fig. 6 ). When incubated with LPA, these early neurons underwent rapid neurite retraction , leading to cell rounding (occurs Ki67-positive cells in LPA-treated cells versus 64.67 ± 5.84% in control conditions, n > 3, P < 0.01; Fig. 2D ) as well as an increase in apoptosis (LPA: 69.86 ± 9.1% of cells were TUNEL-positive versus 40.03 ± 5.9% in control, n > 3, P < 0.01; Fig. 2D ). A similar trend was observed in hESCs, although the decreased proliferation was not found to be statistically signifi cant ( Fig. 3J ) .
Quantifying neurosphere formation frequency does not discriminate between apoptosis and proliferation but provides a reliable and robust measurement of NS/PC expansion and was used here to identify the signaling mechanisms used by LPA during this process. The impact of LPA on neurosphere formation was found not to be mainly through its extracellular receptors LPA 1/3 , as pretreatment with Ki16425 at a dose that is specifi cally antagonistic to LPA 1/3 ( 48 ) did not modify LPA-mediated inhibition of sphere formation in the iPSCs but signifi cantly reduced the effect of LPA on hESC sphere formation ( Figs. 2E and 3B , G ). It is likely that the blockage of these receptors is compensated by the other LPA receptors present in NS/PCs. Due to the lack of commercially available, specifi c LPA receptor antagonists, the involvement of the other receptors was not assessed in this study. Further, we decided not to use siRNA in these experiments because of the poor transfection efficiency due to the three-dimensional structure of the sphere. Instead, siRNA knockdown of ROCKI/II were performed on monolayered NS/PCs as explained below. In the presence of the selective PPAR ␥ antagonist GW9662 ( 49 ), the effect of LPA was not modifi ed, suggesting that LPA does not act through PPAR ␥ to inhibit neurosphere formation ( Fig. 2F ) .
In all cell lines, the effect of LPA on sphere formation was abolished by pretreatment with either the specifi c Rho inhibitor C3 exoenzyme ( 50 ) ( Figs. 2G and 3C , H ) or with the p160 ROCK inhibitor Y27632 used at a dose specifi c to p160ROCK inhibition ( 51 ) ( Figs. 2H and 3D, F ) , which alone have no marked effect, indicating that LPA acts through the Rho/ROCK pathway to inhibit neurosphere formation. Furthermore, when cells were incubated with PTX, which ADP-ribosylates ␣ i proteins, LPA's effect was maintained ( Figs. 2I and 3E, I ), suggesting that LPA's effect is not G i/o mediated and is consistent with a G 12/13 Rho-mediated mechanism. This data was confi rmed by measuring apoptosis and proliferation of NS/PCs in the presence of LPA and Y27632 ( Figs. 2D and 3J ) . The sole application of Y27632 did not modify basal proliferation or apoptosis ( Figs. 2D and 3J ). As shown in Fig. 2 in iPS1 , LPA-induced apoptosis and LPA-reduced proliferation were abolished by Y27632 ( Fig. 2D ) . Thus, this data indicate that LPA acts through the Rho/ROCK pathway to inhibit neurosphere formation, at least by increasing cell apoptosis and by decreasing proliferation in iPS1.
LPA induces RhoA activation
To confi rm that LPA modulated NS/PC expansion by activation of the Rho/ROCK pathway, we measured Rho activity in NS/PCs by using an adherent culture of human NS/PCs derived from dissociated neurospheres. This protocol was favored over spheres, as the monolayer NS/PC culture ensures an even exposure of LPA to all cells at the Supplemental Material can be found at: Fig. 3 . LPA inhibits neurosphere formation of iPS2-and hESC-derived NS/PCs. Quantifi cation of neurosphere formation in the absence (Control) or presence of LPA at various concentration in iPS2 (A-E) and hESCs (F-I), with or without Ki16425 (10 µM, B, G), C3 (1 ng/ml, C, H), Y27632 (1 µM, D, F), and PTX (10 ng/ml, E, I). (J) Quantifi cation of proliferation (Ki67) and apoptosis (TUNEL) in hESC neurospheres treated or not (Control) with LPA (10 µM) and/or Y27632 (1 µM) for seven days. The specifi c inhibitors were preincubated as specifi ed in Materials and Methods prior to LPA addition and maintained in the culture medium for the entire differentiation period. Each panel represents a pool of at least three independent experiments, and data are expressed as means ± SEM. The statistical analysis was established by one-way ANOVA analysis; * P < 0.05; ** P < 0.01; *** P < 0.001. LPA, indicating that the mechanisms mediated by LPA are fundamental in neural differentiation and are not infl uenced by other variables often observed between different hESC/iPSC lines ( 53 ) .
Our results show that both undifferentiated hPSCs and neural differentiated hPSCs express LPA [1] [2] [3] [4] [5] mRNA, confi rming our previous RT-PCR data ( 8, 39, 54 ) , and they show that LPA 2 and LPA 4 are the most abundant mRNA in undifferentiated hPSCs and neurospheres. Modulation in the receptor expression profi le was observed following neural differentiation with an upregulation of LPA 1 mRNA during the early neural commitment of hPSCs (noggin-treated stage), followed by its downregulation during later differentiation (neurosphere stage). The mRNA expression profi le in hPSC-derived neurospheres shared some similar trends to the profi le observed in hESC-derived NEP ( 41 ) and in the monolayer NS/PCs, with LPA 1,2,4 being the most expressed mRNA. The low level of sPLA 2 expression and the presence of ATX mRNA following neural differentiation, as exemplifi ed in this data, are consistent with the fact that ATX expression is associated with neurogenesis ( 55 ) .
As LPA 1 shows its highest expression level at the noggin stage, we assessed its involvement in neurosphere formation as readout of the impact of LPA on NS/PC expansion. Using the LPA 1-3 antagonist Ki16425, we observed no signifi cant effect of this treatment on LPA's effect in iPSCs and a partial inhibition in hESCs, suggestive that other receptors are involved in the inhibition of NS/ PC expansion by LPA. This is consistent with the fact that LPA 2, 4 are the most abundant mRNAs in NS/PCs from all cell lines. LPA receptors are coupled to multiple G proteins, with LPA 1-5 coupled to G q, LPA 1,2,4,5 coupled to G 12 , LPA [1] [2] [3] [4] coupled to G i , and LPA 4,5 also coupled to G s ( 1 ). PTX did not affect LPA's effect on sphere formation, suggesting that LPA acts independently of ␣ i , either through G 12 and/or G q and/or the ␤ ␥ subunits of G proteins. This is highly likely given that the main receptors present at either the noggin stage or neurosphere stage (LPA 2, 4 > 1 ) signal through G q and G 12 . Additionally, as LPA's effect on NS/PC expansion is Rho/ROCK-mediated, it is also probable that the mechanism is G 12 dependant ( 56 ). Further, we showed that LPA inhibits neuronal differentiation of iPSC-derived NS/PCs through the PI3K/Akt and Rho/ROCK pathways, which are likely to be mediated by ␤ ␥ and G 12 , respectively ( 56 ) , and which is consistent with our previous data obtained with hESCs ( 39 ) . Lastly, we describe that LPA induces morphological rearrangements of early neurons in a Rho/ROCK manner, presumably mediated by G 12 . Altogether, this data demonstrates the importance of LPA receptor-mediated signaling along the whole neural differentiation process.
We found that LPA promoted apoptosis of early human NS/PCs, as revealed by neurosphere formation assay, which is consistent with some NS/PC and neuroblast studies performed in rodents ( 16, 17, 38, 57, 58 ) but differs with others in which LPA improves cell survival ( 16, 38 ) or proliferation ( 13, 35, 59 ) . In human cells, we previously showed that LPA does not modify apoptosis of older hESCderived NS/PCs ( 39 ) as, when two-week-old hESC-derived within minutes; Fig. 6A-D and supplementary video I) . These effects were dose dependent, starting at 1 µM, and reversible ( Table 1 and Fig. 6E-G ) . The reversibility took longer when compared with the rapid retraction observed in the presence of LPA, but it suggest that the neurite retraction was not the result of cell death.
LPA-induced morphological rearrangements could be prevented by preincubation with C3 exoenzyme or Y27632 ( Table 1 , Fig. 6H-K , and supplementary video I) , indicating that LPA acts through the Rho/ROCK pathway to induce neurite retraction in early neurons derived from hPSCs. PTX and LY294002 had no effect on LPA-induced neurite retraction ( Table 1 ), indicating that this mechanism is G ␣ i and PI3K/Akt independent. Similar data were observed in early neurons derived from monolayered NS/ PC cultures ( Fig. 4K, L ) . To further elucidate LPA's role in neural development, we analyzed the impact of LPA on the actin-myosin cytoskeleton, assessing cofi lin and MLC, respectively, as these proteins are downstream effectors of ROCK ( 52 ) . These experiments were performed on monolayered NS/PCs by immunohistochemistry to assess localization of phospho-cofi lin and phospho-MLC. As shown in Fig. 6L -O , although we did not observe an effect of LPA on phospho-cofi lin, LPA induced the phosphorylation of MLC, suggesting that it induces morphological rearrangements through modifi cation of myosin.
DISCUSSION
LPA is bioactive lipid known to affect most cell types of the nervous system. Limited studies have addressed LPA's role in the human CNS and in human neural cells. We previously described that LPA inhibits the neuronal differentiation of hESC-derived NS/PCs and briefl y reported that LPA inhibits neurosphere formation of hESCs ( 39 ) . Here we established a comprehensive in vitro system to assess the role of LPA at multiple stages of human neural differentiation using both hESCs and human iPSCs. We assessed whether these two different sources of human NS/PCs are equivalent in terms of LPA's effects upon neuralization by describing LPA [1] [2] [3] [4] [5] , ATX , and s PLA 2 mRNA expression and by assessing whether effects previously observed with hESCs were retrieved in human iPSCs. We also characterized how LPA modifi es NS/PC expansion and the morphology of early human neurons. We observed a similar pattern of effects of LPA throughout the neural differentiation of hESCs and iPSCs. The three lines tested expressed LPA receptors and ATX and sPLA 2 mRNA with a similar profi le. In all NS/PCs tested, LPA increased cell death and inhibited neuronal differentiation without modifying glial differentiation. Furthermore, LPA induced morphological rearrangements in early neurons differentiated from NS/PCs. In iPSC-derived NS/PCs, LPA also signifi cantly decreased proliferation, while a similar trend was observed in hESC-derived NS/PCs but without reaching statistical signifi cance. Hence, our data shows generally consistent results across different iPSC and hESC lines, with some minor interline differences in responsiveness to tiation of human iPSCs, which is in agreement with our previous study using hESCs ( 39 ) and with data obtained in rodents ( 58 ) ; although other studies found opposite effects in various NS/PCs and neuroblasts ( 14, 17, 18, 38, 59, 60 ) .
Even though using similar protocols of maintenance of NS/PCs as monolayers, it is interesting to note that we observe some variations with data obtained on hESC-derived NEP ( 41 ) . In particular, as shown in Fig. 4 , we did not observe the growth effect of low doses of LPA on monolayers of NS/PCs described by others ( 41 ), but we showed neurospheres plated in conditions allowing differentiation were incubated with LPA for 18 h, no modifi cation in apoptosis or proliferation was detected by TUNEL or BrdU assays, respectively ( 39 ). Here we confi rmed this data using human iPSC-derived neurospheres. Further, others demonstrated that LPA increases growth of hESC-derived NEP ( 41 ) , an effect observed at a concentration of up to 0.1 µM. In this study, that concentration already inhibited sphere formation but did not signifi cantly affect monolayered NS/PCs. Similarly, LPA inhibits neuronal differentiation but not glial differen- the discrepancies in LPA-mediated effects between the studies, which could refl ect a variation in the developmental state (either more or less restricted) of the human NS/PC populations in use.
LPA has been extensively studied for its prominent effect in inducing cytoskeletal rearrangements. In particular, LPA is shown to induce neurite retraction and cell rounding through the Rho/ROCK pathway in rodent immortalized neuroblasts and PC12 ( 26, 61 ) . We observed a similar pattern of morphological changes in early human neurons, which, following exposure to LPA, underwent immediate and rapid retraction, cell rounding, and migration to form cell clusters and compaction in a Rho/ROCK-dependent manner. Interestingly, in hESC NEP, LPA induced ROCK-dependent morphological rearrangements, but these were observed to be slow, peaking around 5 h ( 41 ) .
that LPA induces apoptosis of the monolayer NS/PCs at a dose that was not previously tested in hESC NEP. Our data, using two different sources of human NS/PCs and two different protocols for maintenance (neurospheres and monolayers), indicates that the observed pro-apoptotic effects of LPA are consistent, regardless of the NS/PC origin. It is thus likely that the variations between our data and those of Hurst and colleagues in terms of cell growth at low concentrations of LPA are due to a difference in the populations of human cells studied. In particular, the main difference between the protocols for generating a monolayer of NS/PCs is in the derivation of the NS/PCs themselves. We use dissociated neurospheres to obtain a monolayered culture, whereas the NEP used by Hurst and colleagues were directly obtained from hESCs without going through a neurosphere stage ( 41, 46 ) . This variation in protocol might account for Supplemental Material can be found at: ( 74 ) . Following CNS injury, ischemia, or events that damage the blood brain barrier, LPA-like activity increased within the cerebrospinal fl uid , levels of LPA within the CNS increased up to 10 µM (75) (76) (77) (78) , and levels of ATX increased within astrocytes neighboring a lesion of the adult rat brain ( 79 ) . Our data using human cells suggest that the presence of LPA in regions of neurogenesis within the CNS may modify NS/PC survival and differentiation. Our data also suggest that high levels of LPA have the ability to be pro-apoptotic on human NS/PCs, to bias their differentiation toward glial cells and to induce neurite retraction and cell rounding of early neurons and thus limit the regenerative responses to injury. This is relevant to endogenous neurogenesis and might explain low levels of neurogenesis observed following trauma, with LPA being a limiting factor of genesis. This fi nding is also relevant to transplantation of human stem or progenitor cells within the CNS, as the infl ammation present or generated by the transplantation procedure itself may induce increased levels of LPA which could limit neurogenesis and repair. Our data also suggest that neurogenesis may be enhanced by blockers of LPA signaling, such as LPA antibodies that we recently demonstrated were able to abolish LPA's effect on human NS/PCs in vitro and improve neuronal survival and functional recovery following spinal cord injury in vivo ( 80 ) . Such a mechanism has already been proved with sphingosine-1-phosphate, as blocking its signaling enhances endogenous NS/PC migration to the injury site following trauma ( 81 ) .
CONCLUSION
LPA plays a broad role in human NS/PCs and their neural derivatives, regulating expansion, differentiation, and morphology. We showed that in hPSC-derived NS/PCs, LPA increases apoptosis, decreases proliferation, inhibits neuronal differentiation, and induces rapid morphological rearrangements in early neurons. All these effects are at least Rho/ROCK dependent. We observed that the effects of LPA on NS/PCs are insensitive to PTX treatment, indicating no involvement of ␣ i but suggestive of the involvement of ␣ 12 , ␣ q , or ␤ / ␥ in these biological effects. LPA-induced activation of Rho/ROCK is likely to be G 12 mediated, as this is the common upstream G protein for Rho and has been reported to be involved in the pro-apoptotic effect of LPA through LPA 1,2,4 ( 16 ) . Thus, our data demonstrate the consistency in the effect of LPA across various sources of human NS/PCs, rendering hESCs and human iPSCs valuable in vitro models for studying lysophospholipid signaling in human neural cells. Our data also highlight the importance of the Rho/ROCK pathway in human NS/PC expansion and differentiation. It is thus possible that blocking LPA signaling in vivo, in which levels increase following trauma, would enhance neurogenesis.
The authors thank Guizhi Sun and Daniella Herszfeld (Monash University) for their help in setting up monolayer cultures of The importance of the Rho/ROCK pathway in stem cell survival is now established. The ROCK inhibitor Y27632 signifi cantly increases hESC single-cell survival ( 62, 63 ) and NS/PCs following neurosphere dissociation ( 64 ) . Further, upon dissociation to single cells, the Rho/ ROCK pathway is activated and responsible for modulating cell-cell contact-induced apoptosis in hESCs ( 65 ) , NS/PCs ( 64 ), and neurons ( 66 ) , an effect associated with MLC phosphorylation in hESCs ( 47 ) . Moreover, in neurons, Rho/ROCK activation induces apoptotic membrane blebbing by stimulating MLC phosphorylation ( 66 ) and has associations to neuronal death following spinal cord injury ( 67 ) . Other data suggest that ROCK inhibition may not act directly by reducing apoptosis but rather by desensitizing cells to their environment and thus limiting apoptosis ( 68 ) .
Our data showing LPA's activation of RhoA is in line with data obtained by others in other stem and progenitor cells ( 1 ) and are the fi rst demonstration of human-derived NS/PCs at various stages of differentiation. A large body of evidence shows that LPA acts through the Rho pathway to modify cell survival, apoptosis, and proliferation in diverse types of cells by mediating cell shape/focal adhesion alteration ( 38, 69, 70 ) . Our current data demonstrate that LPA activates RhoA in human NS/PCs and implicate this pathway in LPA-induced apoptosis, decreased proliferation, and together with the PI3K/Akt pathway, LPA inhibition of neuronal differentiation of human NS/PCs. Furthermore, activation of this pathway is essential to LPAinduced morphological rearrangements in human NS/ PC-derived early neurons.
Adult NS/PCs are present in the CNS, predominantly in neurogenic regions, such as the subventricular zone and hippocampus. They have been reported to migrate to sites of injury and tumors ( 71 ) , effects likely to be linked to the repair of damaged tissue. Furthermore, evidence suggests that NS/PCs contribute to neurogenesis in the adult mouse and human following stroke ( 72, 73 ) . Similar data were observed following brain injury in the juvenile rat LPA's effect in neurite retraction among tested agents in human NS/PCs. Early neurons differentiated from hPSCs were incubated or not with LPA and/or Y27632 (1 µM, 30 min preincubation), C3 transferase (1 ng/ml, 4 h preincubation), PTX (10 ng/ml, 18 h preincubation), and LY 294002 (10 µM, 30 min preincubation). +, retraction; Ϫ , no retraction. Each treatment assessment is representative of at least three independent experiments.
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